LSL Videos
PITCHING AND FUNDRAISING IN THE NEW NORM
-
Pitching And Fundraising In The New Norm
Raising money for a startup biopharma is a task that never ends, even during a pandemic. This is good. Because while some industries experienced significant financial collapse last year, biopharma was perfectly positioned to provide COVID-19 solutions, which it has at an unprecedented pace.
PREPARING FOR A VIRTUAL J.P. MORGAN HEALTHCARE CONFERENCE (JPM)
-
Preparing For A Virtual J.P. Morgan Healthcare Conference (JPM)
Unfortunately, like so many in-person events negatively impacted by COVID-19 last year, the 2021 JPM conference will be 100% virtual. So, we thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique JPM and how those preparations are different than what they’ve done in the past.
- A Banker’s Perspective Of Attending And Working JPM
- The Contrast Between Attending JPM As A Big Pharma Versus A Small Cap
- How JPM Has Changed In The Last 14 Years
- Deals Of Consequence That Evolved Out Of JPM
- How To Prepare For A Virtual JPM
- Will A Virtual JPM Result In Less Sense Of Urgency Or Changes In Pitching
MANUFACTURING AND SUPPLY CHAIN RISK MITIGATION STRATEGIES AMIDST COVID-19
-
Manufacturing And Supply Chain Risk Mitigation Strategies Amidst COVID-19
Three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies’ manufacturing and supply chains amidst a pandemic.
TACKLING HR IN BIOPHARMA DURING A PANDEMIC
-
Tackling HR In Biopharma During A Pandemic
Three biopharma VPs of HR discuss the challenges of continued operations amidst COVID-19 initiated lockdowns, along with some of the best practices implemented.
ACCELERATING YOUR BIOPHARMA STARTUP'S PATH TO THE CLINIC
-
Accelerating Your Biopharma Startup’s Path To The Clinic
Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, and Dara Lockert, founder and executive director of Spannerwerks, a consultancy, share best practices and lessons learned during the drive to get a biopharma startup to the clinic as quickly as possible.
- Applying A Partnering Approach To Meeting Unmet Medical Need
- Why Taking A Partnered Approach To The Clinic Makes Sense
- Determining What Expertise Is Needed In A Partnered Drug Development Model
- How To Create Interest And A Sense Of Urgency In An Outsourced Drug Development Model
- The Outsourcing Selection Process
- What To Avoid And Pearls Of Wisdom In A Partnered Drug Development Model
WHAT'S HAPPENING ON THE FRONT LINES OF COVID-19: A CEO ROUNDTABLE ON TECHNOLOGIES IN DEVELOPMENT FOR THE CURRENT PANDEMIC
-
What’s Happening On The Front Lines of COVID-19: A CEO Roundtable On Technologies In Development For The Current Pandemic
Four biopharma CEOs and cofounders discuss what their organizations are doing to spur the development of diagnostic tests, therapeutics, and vaccines to turn the tide on the COVID-19 pandemic.
- What is XPRIZE Doing To Help In The Battle Of COVID-19?
- The Founding Of COVAXX — A Dedicated COVID-19 Vaccine Company
- The How And Why Behind A CNS Company Pivoting To Develop A Treatment For COVID-19
- What Is Lineage Cell Therapeutics Doing To Tackle COVID-19?
- How The FDA Has Been Able To Adjust To Accelerate COVID-19 Therapeutic Development
- Thoughts On Vaccinating For COVID-19 — Should A Vaccine Be Approved
LEADING THROUGH ADVERSITY: A CEO ROUNDTABLE ON DRUG DEVELOPMENT DURING A PANDEMIC
-
Leading Through Adversity: A CEO Roundtable On Drug Development During A Pandemic
Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic.
- How Is The Overall Environment For Development Of Innovative Medicines And Biomedical Technologies?
- Adapting Drug Development During COVID-19
- How Has COVID-19 Stalled Drug Development
- Challenges And Solutions Around Diversity And Inclusion In Clinical Trials During A Pandemic
- The Pandemic As A Catalyst For Drug Development
- Six Minutes On Helping Elected Officials With Win-Win Policy Making
PREPARING FOR THE NEW BIOMANUFACTURING FRONTIER: A FIRESIDE CHAT WITH FLUGEN'S ANDY SKIBO
-
Preparing For The New Biomanufacturing Frontier: A Fireside Chat With FluGen’s Andy Skibo
At the Generis 2020 American Biomanufacturing Summit (July 21 – 23), Andy Skibo, chief manufacturing officer for FluGen, discusses the challenges around developing and delivering a COVID-19 vaccine on a significantly shortened timeframe, plus other opportunities for improving biomanufacturing and its supply chain to support future therapies.
BIOPHARMA AND THE MANAGEMENT OF WALL ST. DURING A PANDEMIC
-
Biopharma And The Management Of Wall St. During A Pandemic
The volatility of the U.S. stock market in the first half of 2020 has even the heartiest investor queasy. But how about the leaders of such publicly traded companies? We conduct a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies to learn how they are leading their organizations while also managing the expectations of Wall Street during the COVID-19 pandemic.
- Taking On Debt And Executing A Public Offering During COVID-19
- Why Chimerix Pivoted To Take On COVID-19
- Managing Clinical Trials And Supply Amidst COVID-19 Outbreak
- Serving Traumatic Injury Patients And Surgeons During Pandemic Panic
- Biopharma CEOs Weigh In On Working With Wall St. During Pandemic Pandemonium
- AxoGen CEO Details Approach To Crisis Management During COVID-19
- Don’t Let Efforts To Solve COVID-19 Capsize Decades Of Drug Development Work
- Navigating The Delivery Of Data Via Virtual Conferences And Meetings
LEADERSHIP DURING COVID-19 — A BIOPHARMA CEO ROUNDTABLE
-
Leadership During COVID-19 — A Biopharma CEO Roundtable
Five biopharmaceutical industry CEOs discuss challenges their company's have faced, along with best practices implemented in managing through the COVID-19 chaos.
AN INTERVIEW WITH ROBERT HARIRI, M.D., PH.D., CEO AND FOUNDER OF CELULARITY
-
An Interview with Robert Hariri, M.D., Ph.D., CEO and founder of Celularity
A video of Life Science Leader chief editor, Rob Wright, interviewing Robert (Bob) Hariri, M.D., Ph.D., CEO and founder of Celularity, at the 2019 CNS Summit.
VIRTUAL ROUNDTABLES
During the COVID-19 pandemic of 2020, Life Science Leader decided to engage with some of our executive-level readers via Zoom conference calls. These virtual roundtables were hosted by our Chief Editor Rob Wright and then broken up into shorter clips based on specific questions or topics discussed during the full-length call.